Arthritis & Rheumatism, Volume 62,
November 2010 Abstract Supplement

Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Atlanta, Georgia November 6-11, 2010.


DC-STAMP (Dendritic Cell-Specific Transmembrane protein), a Potential Biomarker To Predict the Risk of Psoriasis Patients in Developing Psoriatic Arthritis.

Chiu1,  Yahui Grace, Shanmugarajah3,  Sutha, Panepento1,  Ben, Eder2,  Lihi, Chandran2,  Vinod, Gladman2,  Dafna, Moorehead1,  Sharon

AIR Unit, University of Rochester, Rochester, NY
UHN-Toronto Western Hospital, Toronto, ON, Canada
UHN-Toronto Western Hospital, Toronoto, ON, Canada

Purpose:

20% of psoriasis (Ps) patients (pts) develop psoriatic arthritis (PsA) within 10 years of Ps onset. Identification of an arthritis biomarker in Ps pts would facilitate early intervention and possibly delay and/or prevent onset of PsA. Previously, we reported an increased frequency of circulating osteoclast precursors (OCP) in one third of Ps pts without arthritis. We hypothesized that DC-STAMP (Dendritic Cell-Specific Transmembrane protein), a transmembrane protein that is required for the fusion of monocytes during osteoclast (OC) formation, may serve as an arthritis susceptibility biomarker in Ps.

Methods:

We previously identified 4 major DC-STAMP expression patterns in human PBMC with an anti-DC-STAMP antibody by flow cytometry. Most healthy controls have low OCP and show DC-STAMP pattern I, whereas PsA pts demonstrate elevated OCP and are more likely to manifest DC-STAMP pattern IV. We analyzed DC-STAMP expression patterns by flow cytometry and OCP frequency in cultured monocytes in a longitudinal cohort of 24 Ps pts. They were assessed by rheumatologists based on standard criteria and did not have PsA. They have been followed for 3 years on average.

Results:

Table 1 summarizes the baseline clinical features, DC-STAMP patterns and frequency of OC in 24 pts. Two, 6, 10, 6 Ps pts manifested DC-STAMP pattern I, II, III, and IV, respectively (column (a) & (b)). The OCP frequency (mean±standard deviation) is shown in column (c). Within 3 years, 2 pts developed PsA by the CASPAR criteria (column (f)). Their demographics and clinical variables are depicted in Table 2.

Conclusions:

Data from this longitudinal cohort registry suggest that DC-STAMP is a potential marker to predict development of PsA in Ps pts. Two pts who developed PsA have DC-STAMP pattern III and pattern IV, the most common patterns seen in PsA pts. Additional studies are required to further define the potential of DC-STAMP as an arthritis susceptibility biomarker.

Table 1.

(a) DC-STAMP Pattern(b) # of subjects(c) OCP frequency (per 106 monocytes)(d) Average of age(e) PASI score(f) # of pts develop PsA
I247 ± 25624.60
II6279 ± 365572.90
III10380 ± 398498.21
IV61063 ± 954364.11

Table 2.

SubjectGenderAgeDC-STAMP patternOC frequency (per 106 monocytes)PASI score 3 years agoPASI score after arthritis onsetYears from Ps to PsA
#1Female58III5803.53.15.7
#2Female48IV11856.612.24.7

To cite this abstract, please use the following information:
Chiu, Yahui Grace, Shanmugarajah, Sutha, Panepento, Ben, Eder, Lihi, Chandran, Vinod, Gladman, Dafna, et al; DC-STAMP (Dendritic Cell-Specific Transmembrane protein), a Potential Biomarker To Predict the Risk of Psoriasis Patients in Developing Psoriatic Arthritis. [abstract]. Arthritis Rheum 2010;62 Suppl 10 :521
DOI: 10.1002/art.28290

Abstract Supplement

Meeting Menu

2010 ACR/ARHP